InflaRx to release Q1 2026 financial results on May 7, no conference call planned.

InflaRx N.V., a biopharmaceutical company focused on anti-inflammatory therapies, announced it will publish its financial and operating results for the first quarter of 2026 on May 7, before the market opens. The company will not hold a conference call to discuss the results. InflaRx is known for its lead drug candidates izicopan and vilobelimab, targeting inflammatory diseases by inhibiting the complement system. Investors will be watching for updates on the progress of these therapies and any regulatory developments.